Dapagliflozin (SGLT2 Inhibitor)
Treatment for Chronic kidney disease due to glomerulonephritis
Typical Dosage: 10 mg once daily
Effectiveness
82%
Safety Score
65%
Clinical Trials
50
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg once daily
Time to Effect
2-3 months for kidney/CV benefits
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
22(Treat 22 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$200
Side Effect Mgmt:$100
Total Annual:$5,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$25,000/QALY
QALYs Gained
1.4
Outcome-Based Costs
Cost per Responder
$6,235
Comparison vs RAS inhibitor alone
Cost Difference
+$5,300/year
More expensive
QALY Difference
+1.40 QALYs
Better outcomes
Dominance
No dominance
Dapagliflozin (SGLT2 Inhibitor) Outcomes
for Chronic kidney disease due to glomerulonephritis
Efficacy Outcomes
Overall Effectiveness
+82%
Response Rate
+85%
Common Side Effects
Genital mycotic infections
+7%
Urinary tract infections
+3%
Volume depletion/hypotension
+1.5%
Euglycemic DKA
+0.05%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov